Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,816.89
(
-0.11%
)
US TECH 100
24,499.60
(
0.38%
)
Dow Jones
47,916.57
(
-0.56%
)
Brent Oil
92.41
(
0.00%
)
Bitcoin
72,861.05
(
-0.16%
)
News Focus
News Focus
Post# of 257382
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122860
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 83408

Thursday, 09/10/2009 1:06:47 PM

Thursday, September 10, 2009 1:06:47 PM

Post# of 257382

VVUS on the IP issue: I have posted sometime ago at SI that JNJ holds a method-of-use patent covering the use of topiramate (Topamax) in obesity and there are overlapping claims with Qnexa patentm so I believe JNJ has a ground to sue.

Since this patent isn’t worth much in practice, VVUS doesn’t have much to lose even if JNJ does decide to sue.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today